Whether in-frame fusion or truncation, most MYB-rearrangement cases showed high levels of MYB expression, when compared within an archival cohort of  > 1000 CNS tumor cases profiled in the course of clinical testing on the same RNA Exome platform (Fig. 4). This evidence concerns the gene MYB and central nervous system neoplasm.